Vanda Pharmaceuticals (VNDA) – Analysts’ Recent Ratings Changes

Vanda Pharmaceuticals (NASDAQ: VNDA) has recently received a number of price target changes and ratings updates:

2/14/2019 – Vanda Pharmaceuticals had its “reduce” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $26.00 price target on the stock. They wrote, “. We reiterate our Neutral rating and reduce our PT to $26 from $30 for VNDA based on lowered 2019 revenue projections. On Wednesday, Vanda reported 4Q18 revenues of $32.4M for HETLIOZ and $20.6M for Fanapt, which were in line with our estimates. Vanda ended 4Q18 with cash of ~$257M, sufficient to fund operations through clinical milestones such as the first P3 study of tradi' in atopic dermatitis. Although we project YoY growth for HETLIOZ in 2019, we do not view it as a source of underappreciated value. However if label expansion into SMS is achieved (pending FDA input on capital efficient next steps), this could prove to be a tractable, growth driving opportunity.”” 2/14/2019 – Vanda Pharmaceuticals was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating. 2/14/2019 – Vanda Pharmaceuticals had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $40.00 price target on the stock. They wrote, “We believe shares of VNDA should find some relief after the recent volatility (shares down -26% since 2/5 vs. S&P 500 which is up +1%) which has largely been driven by the news of the partial clinical hold (PCH) on tradipitant and the unsealed whistleblower lawsuit, but also the fact VNDA didn’t issue preliminary results at the JP Morgan conference in January which it had normally done in years past. We think the 4Q results and 2019 guidance should get investors more comfortable that VNDA’s base business (Hetlioz and Fanapt) continues to be generally healthy with a decent growth profile.”” 2/14/2019 – Vanda Pharmaceuticals had its price target lowered by analysts at Oppenheimer Holdings Inc. from $29.00 to $21.00. 2/10/2019 – Vanda Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating. 2/7/2019 – Vanda Pharmaceuticals was downgraded by analysts at TheStreet from a “b-” rating to a “c+” rating. 2/6/2019 – Vanda Pharmaceuticals was downgraded by analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating. They now have a $30.00 price target on the stock, down previously from $38.00. 2/6/2019 – Vanda Pharmaceuticals had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They wrote, “We believe VNDA’s decision to sue the FDA for what it feels are unnecessary animal studies” and due to the company’s current refusal to run these studies having resulted in a partial clinical hold on tradipitant, this will certainly raise questions among investors about the clinical timelines for this program and whether or not management is really focused on creating value for its shareholders.”” 2/4/2019 – Vanda Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating. 2/4/2019 – Vanda Pharmaceuticals was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating. 1/24/2019 – Vanda Pharmaceuticals was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.

Vanda Pharmaceuticals stock traded down $0.40 during trading on Thursday, hitting $18.75. The stock had a trading volume of 479,275 shares, compared to its average volume of 1,024,128. Vanda Pharmaceuticals Inc. has a 1 year low of $13.88 and a 1 year high of $33.44. The company has a market cap of $1.04 billion, a price-to-earnings ratio of 39.06, a PEG ratio of 6.30 and a beta of 0.70.

Get Vanda Pharmaceuticals Inc alerts:

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, February 13th. The biopharmaceutical company reported $0.19 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.22. Vanda Pharmaceuticals had a return on equity of 9.80% and a net margin of 13.05%. The business had revenue of $53.04 million for the quarter, compared to the consensus estimate of $51.56 million. During the same quarter in the prior year, the business earned ($0.04) earnings per share. Vanda Pharmaceuticals’s revenue for the quarter was up 19.8% on a year-over-year basis. Equities analysts anticipate that Vanda Pharmaceuticals Inc. will post 0.22 earnings per share for the current year.

In other Vanda Pharmaceuticals news, SVP Gian Piero Reverberi sold 1,130 shares of the stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $26.59, for a total transaction of $30,046.70. Following the sale, the senior vice president now owns 136,569 shares in the company, valued at $3,631,369.71. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Mihael Hristos Polymeropoulos sold 38,166 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $19.41, for a total value of $740,802.06. Following the sale, the chief executive officer now owns 1,217,136 shares in the company, valued at approximately $23,624,609.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 81,701 shares of company stock worth $1,755,624. 7.80% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the business. Advisor Group Inc. lifted its position in shares of Vanda Pharmaceuticals by 66.2% during the fourth quarter. Advisor Group Inc. now owns 2,916 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 1,161 shares in the last quarter. LS Investment Advisors LLC lifted its position in shares of Vanda Pharmaceuticals by 109.3% during the fourth quarter. LS Investment Advisors LLC now owns 3,662 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 1,912 shares in the last quarter. Neuburgh Advisers LLC purchased a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth $132,000. South Dakota Investment Council purchased a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth $167,000. Finally, Amalgamated Bank purchased a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth $214,000. Hedge funds and other institutional investors own 99.33% of the company’s stock.

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Further Reading: Google Finance